Search
Jul 19, 2024
GRO Biosciences announced a $60 million series B today to help advance its pipeline that is rooted in adding non-standard amino acid (NSAA) chemistries to therapies.
Co-founder and CEO Dan Mandell discusses the company’s approach, and describes how this will allow GRObio to advance its lead program for...
Jul 18, 2024
The founder of Click Therapeutics on the digital therapeutics space and the regulatory opportunity for combining medicines with apps
David Klein describes how the digital therapeutics space works and highlights Click's programs and partnerships with large pharmaceutical...
Jul 17, 2024
Stevenage, UK based Antikor Biopharma is developing ADCs using 'OptiLinked' smaller antibody fragments
CEO Mahendra Deonarian describes the potential advantages of this approach over traditional ADCs and talks about the company's lead...
Jul 17, 2024
Stevenage, UK based Autifony Therapeutics has been building a CNS pipeline from its expertise in ion channel drug discovery
Founder & CEO Charles Large describes the scientific foundation Autifony has built in ion channel science and how the company is...
Jul 17, 2024
Stevenage, UK based Spur Therapeutics is readying to take its gene therapy for Gaucher disease into phase 3
CEO Michael Parini describes how clinical results Spur has seen to date in six patients, with more data to come later this year, has...
Jul 16, 2024
Daiichi Sankyo's global head of R&D talks antibody-drug conjugates and more at the company's "Pharma Day" event in Kendall Square
From a partnering event being held at MassBio's HQ in Kendall Square, Ken Takeshita describes Daiichi's targets under development beyond...
Jul 12, 2024
The Co-CEOs of Amylyx discuss Wednesday's news that they have acquired a GLP-1 antagonist as a new pipeline asset
Josh Cohen and Justin Klee explain why they chose this program, and what the potential timeline looks like for a phase 3 trial. Plus, an...
Jul 11, 2024
The Co-Founder and CEO of Philadelphia based BioPhy describes how he sees AI playing out across the biopharma landscape
Dave Latshaw II predicts how AI might affect organizations of different sizes in biopharma and explains the various ways BioPhy is using...
Jul 11, 2024
Stifel's Paul Matteis joins BiotechTV for Analyst Thursdays from Boston
He provides an in-depth discussion on this week's uniQure data, and upcoming data from Lexeo. Plus, comments on Alnylam, Dyne,...
Jul 10, 2024
Philadelphia-based Passage Bio is aiming to treat frontotemporal dementia by using an AAV gene therapy to boost progranulin levels in the brain
CEO William Chou describes the scientific rationale for elevating progranulin, what the company has seen in the first three patients...
Jul 10, 2024
Flagship Pioneering's founder & CEO Noubar Afeyan discusses his firm's $3.6B fundraise today
Noubar Afeyan describes some areas that he sees the funding being deployed, his take on the current state of biotech, the IPO market,...
Jul 9, 2024
Get to know Allucent -- a full-service, global provider of comprehensive drug development solutions for small and mid-sized biopharmas.
They're on a mission to help bring new therapies to light. Here's how they can help you. Learn more: Allucent.com #sponsored
Jul 7, 2024
London based Myricx Bio announced a £90M (~$114M) series A financing today, one of the largest in recent years in the UK region
A developer of ADCs today, CEO Robin Carr describes how the company’s N-myristoyltransferase (NMT) payload approach sets them apart.
Jul 3, 2024
Stifel analyst Alex Thompson joins BiotechTV for Analyst Thursdays and talks I&I ahead of the July 4th holiday
Alex Thompson gives his general take on I&I and comments on argenx, Immunovant, Ascendis, Celldex, Third Harmonic, Apogee, Spyre,...
Jul 3, 2024
Mereo BioPharma’s CEO discusses recent setrusumab data in Osteogenesis Imperfecta and the future of alvelestat
Denise Scots-Knight describes what Mereo and its partner Ultragenyx have seen in setrusumab data over time, and her description of the...
Jul 2, 2024
QIAGEN's CEO describes the latest sample, assay, and bioinformatics technologies that are powering life sciences and molecular diagnostics
Thierry Bernard describes the scientific advances underlying QIAGEN's four business pillars: sample technologies, diagnostic solutions,...
Jul 1, 2024
Disc Medicine's CEO reviews recent EHA data, including learnings about clinical endpoints from the company's lead GlyT1 program
John Quisel describes how bitopertin aims to reduce PPIX, a photosensitiser that makes it painful for patients when exposed to light....
Jun 28, 2024
Spinal Cord Injury Investor Symposium: The CEO of Axonis Therapeutics discusses the importance of KCC2 inhibition in CNS disorders
Joanna Stanicka describes how Axonis is developing a small molecule that is KCC2-potentiating, with the idea to restore the role that...
Jun 28, 2024
Spinal Cord Injury Investor Symposium: A venture investor describes what he looks for when investing in the spinal cord injury space
Ilan Zipkin of Breakout Ventures says his firm looks at how cell therapies can be augmented with other technologies to help them succeed.
Jun 27, 2024
Spinal Cord Injury Investor Symposium: SCI Ventures is philanthropic but has been designed to invest in spinal cord injuries like a VC fund
Founding Managing Director Adrien Cohen describes how this $30M fund has been structured, what typical investments will look like, and...
.png){kind=logo}
